Altre lingue Kura Oncology, Inc.

Azioni

KURA

US50127T1097

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 24/04/2024			Variaz. 5gg	Var. 1 gen.
18,75 ^USD	0,00%		+4,22%	+30,39%

22/04	Kura Oncology, Inc. riceve la designazione di terapia innovativa per Ziftomenib nella LAM NPM1 mutante	CI
14/03	Transcript : Kura Oncology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:00 AM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Sector Update: Health Care Stocks Advance Premarket Monday	22/04
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy	22/04
Kura Oncology Says Potential Leukemia Drug Ziftomenib Gets FDA Breakthrough Therapy Designation; Shares Rise Pre-Bell	22/04
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML	22/04
Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML	22/04
Kura Oncology to Participate in Stifel Targeted Oncology Forum	10/04
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/04
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma	06/03
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma	06/03
KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	04/03
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/03
Kura Oncology: Q4 Earnings Snapshot	27/02
Kura Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results	27/02
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia	26/02
Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia	26/02
Kura Oncology to Participate in Three Upcoming Investor Conferences	22/02
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results	20/02
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Kura Oncology, Inc.

Azioni

KURA

US50127T1097

Altre lingue

Filtri